# Therapeutics Development Core  (Core B)

> **NIH NIH P30** · NORTHWESTERN UNIVERSITY · 2022 · $230,042

## Abstract

PROJECT SUMMARY TO THERAPEUTICS DEVELOPMENT CORE
The goal of the Therapeutics Development Core (Core B) is to establish an efficient platform for
supporting the development and validation of a pipeline of chemical, biological, and cellular
therapeutics for the treatment of a wide spectrum of kidney diseases. Northwestern University (NU) has
been at the forefront of drug discovery for a wide range of diseases, and state-of-the-art infrastructures have
been built that collectively have significantly expanded our therapeutics armamentarium for many diseases
including hematological, oncological, neurological, and rheumatological conditions. However, they have not
been prioritized and tailored to kidney-specific therapeutics development. We propose to fill this gap by
establishing a Therapeutics Development Core within the NU-GoKIDNEY Center. The Therapeutics
Development Core will function as an efficient translational conduit between the Preclinical Models Core (Core
A) and the Clinical and Translational Core (Core C). This Core proposes to provide a “one-stop” shop for
concierge services for access and expert guidance to kidney therapeutics development, with the ultimate goal
of clinical translation. It will be constructed to provide centralized consultation services for developing novel
kidney disease-specific therapeutics to the NU-GoKIDNEY Center investigators for: (1) designing and testing
experimental biological and small molecule therapeutics; (2) designing and testing cellular therapeutics; and
(3) designing and testing nanotechnology-based precision targeting of therapeutic “payloads” to the desired
cells and tissues. Core B will implement a Ph.D.-level Navigator system for maximizing service efficiency and
promoting innovative collaborations. Core B will also use the soon-to-be-launched nephro-HUB to expand the
core user base, track core services, enhance user interactions and promote user collaborations. Core B
Directors and Navigators collectively possess extensive expertise encompassing novel cellular therapeutics
development, virtual drug and biologics design, high-throughput screening platforms for efficiency
determination, and nanotechnology-based precision drug targeting. Core B will formalize and capture this
collective expertise under one roof, and provide investigators of the NU-GoKIDNEY Center with superior
customer service combined with expert guidance in choosing the most efficient route for novel therapeutics
development. By providing these core services, we anticipate that the Therapeutics Development Core will: (1)
accelerate kidney therapeutics development by providing target-specific consultations and navigation through
the processes of therapeutics design, development, validation and production; (2) elevate kidney disease-
specific therapeutics development to the forefront of existing cutting-edge expertise and state-of-the-art
infrastructures in therapeutics development at Northwestern; (3) catalyze and synergize innovat...

## Key facts

- **NIH application ID:** 10460933
- **Project number:** 5P30DK114857-05
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Xunrong Luo
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $230,042
- **Award type:** 5
- **Project period:** 2018-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10460933

## Citation

> US National Institutes of Health, RePORTER application 10460933, Therapeutics Development Core  (Core B) (5P30DK114857-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10460933. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*